RedHill Biopharma (RDHL) Long-Term Debt Issuances (2020)
RedHill Biopharma (RDHL) posted quarterly Long-Term Debt Issuances of -$784000.0 for Q3 2020, down 56.8% quarter-over-quarter from -$500000.0 in Q2 2020.
RedHill Biopharma (RDHL) Long-Term Debt Issuances (2020) Analysis & Trends
RedHill Biopharma (RDHL) has reported Long-Term Debt Issuances for 1 consecutive years, with -$784000.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Long-Term Debt Issuances changed N/A year-over-year to -$784000.0; the TTM figure through Dec 2020 stood at $78.1 million (changed N/A YoY), while the FY2020 annual figure was $78.1 million, changed N/A from the prior year.
- Long-Term Debt Issuances declined to -$784000.0 in Q3 2020 per RDHL's latest filing, from -$500000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $79.3 million in Q1 2020 and bottomed at -$784000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | RedHill Biopharma | 1.99 Bn | 1.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -784,000.00 |
| Sep 30, 2020 | -784,000.00 |
| Jun 30, 2020 | -500,000.00 |
| Jun 30, 2020 | -500,000.00 |
| Mar 31, 2020 | 79.35 Mn |
| Mar 31, 2020 | 79.35 Mn |